Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Lecanemab: Appropriate Use Recommendations

The Journal of Prevention of Alzheimer s Disease(2023)10.14283/jpad.2023.30Source: DataRank Database

Lecanemab: Appropriate Use Recommendations is a research paper published in The Journal of Prevention of Alzheimer s Disease (2023). On theSindex it has a DataRank of 0. It has been cited 822 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access822 citations

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (20 grants)Impact (FWCI 262.62)OA: goldTopics (64)Linked Datasets (2)DataCite Reuse (2)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (11)

L Apostolova,G D Rabinovici,A Atri,Pau Aisen,S Greenberg

Live enrichment

PubMed:37357276 PMC:PMC10313141 OpenAlex:https://openalex.org/W4360591479

NIA NIH HHS

Grant: P20 AG068053

NIA NIH HHS

Grant: R01 AG057739

NIGMS NIH HHS

Grant: P20 GM109025

NIA NIH HHS

Grant: U01 AG057195

NINDS NIH HHS

Grant: U01 NS093334

NIA NIH HHS

Grant: R01 AG053798

NIA NIH HHS

Grant: P30 AG010133

NIA NIH HHS

Grant: P30 AG072959

NIA NIH HHS

Grant: P30 AG072980

NIA NIH HHS

Grant: R35 AG071476

National Institutes of Health

Grant: 5P30AG072980-02

Arizona Alzheimer's Disease Research Center

National Institutes of Health

Grant: 5R35AG071476-02

Alzheimer's Clinical Trial InnOvatioN (ACTION) Initiative

National Institutes of Health

Grant: 5P30AG072959-02

Cleveland Alzheimers Disease Research Center

National Institutes of Health

Grant: 5R01AG053798-02

Global Alzheimer's Platform Trial-Ready Cohort for Preclinical/Prodromal Alzheimer's Disease

National Institutes of Health

Grant: 5U01NS093334-02

Chronic Traumatic Encephalopathy: Detection, Diagnosis, Course, and Risk Factors

National Institutes of Health

Grant: 5P20GM109025-03

COBRE GRANT

National Institutes of Health

Grant: 5U01AG057195-05

Early Onset AD Consortium - the LEAD Study (LEADS)

National Institutes of Health

Grant: 5P20AG068053-03

Nevada Exploratory Alzheimer's Disease Research Center (NVEADRC)

National Institutes of Health

Grant: 5P30AG010133-08

CORE-- EDUCATION AND INFORMATION TRANSFER

National Institutes of Health

Grant: 5R01AG057739-04

Leveraging Neuroimaging Biomarkers to Understand the Role of Social Networks in Alzheimer's Disease

FWCI

262.62

Citation Percentile

1.0%

Citation Trend

2021

2022

2023

2024

2025

2026

goldLicense: cc-by

journalhttps://doi.org/10.14283/jpad.2023.30

publisherhttps://doi.org/10.14283/jpad.2023.30

publisherhttps://api.elsevier.com/content/article/PII:S2274580724001948?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2274580724001948?httpAccept=text/plain

repositoryhttps://pubmed.ncbi.nlm.nih.gov/37357276

Fields of Study

Health Systems, Economic Evaluations, Quality of LifeDementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments03 medical and health sciences0302 clinical medicineHumansApolipoprotein E4Alzheimer DiseaseAntibodies, MonoclonalAmyloidAntibodies, Monoclonal, Humanized

MeSH Terms

Alzheimer DiseaseAmyloidAntibodies, MonoclonalHumansApolipoprotein E4Antibodies, Monoclonal, Humanized

Keywords

MedicineClinical trialDementiaAdverse effectAsymptomaticDiseaseIntensive care medicineInternal medicineAlzheimer’s diseaseMagnetic resonance imaging (MRI)Amyloid ImagingFood And Drug AdministrationPrescribing InformationAccelerated ApprovalAducanumabAmyloid-related Imaging Abnormalities (Aria)DonanemabLecanemabAgingAmyloidCerebrovascularClinical SciencesClinical Trials and Supportive ActivitiesApolipoprotein E4610NeurodegenerativeAlzheimer's DiseaseAntibodies, Monoclonal, HumanizedAntibodiesArticleClinical ResearchAlzheimer DiseaseMonoclonalAcquired Cognitive Impairmentmagnetic resonance imagingHumansCognitive and computational psychologyBiomedical and Clinical SciencesNeurosciencesAlzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD)Antibodies, MonoclonalBrain Disorders6.1 PharmaceuticalsNeurologicalamyloid-related imaging abnormalitiesBiological psychologyPatient Safety

Sustainable Development Goals

SDG 0: Reduced inequalities

Additional file 1 of NeuroEPO plus (NeuralCIM®) in mild-to-moderate Alzheimer’s clinical syndrome: the ATHENEA randomized clinical trial

10.6084/m9.figshare.26653149.v1figshare

Additional file 1 of NeuroEPO plus (NeuralCIM®) in mild-to-moderate Alzheimer’s clinical syndrome: the ATHENEA randomized clinical trial

10.6084/m9.figshare.26653149figshare